Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,628 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06905587 | Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue(EMBRAIN) | recruiting | Phase 3 | 50 | Odense University HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 |
| clinicaltrials |
| NCT04509700 | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | active not recruiting | Phase 2 | 112 | Incyte CorporationINDUSTRY | 17 | Jun 25, 2026 | clinicaltrials |
| NCT05712551 | Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts | completed | — | 4 | Herlev HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04641247 | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | recruiting | Phase 2 | 37 | GlaxoSmithKlineINDUSTRY | 8 | Jun 24, 2026 | clinicaltrials |
| NCT04806412 | Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study. | recruiting | N/A | 100 | Naestved HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | active not recruiting | Phase 3 | 77 | PfizerINDUSTRY | 19 | Jun 22, 2026 | clinicaltrials |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-301) | terminated | Phase 1 / Phase 2 | 260 | AmgenINDUSTRY | 26 | Jun 22, 2026 | clinicaltrials |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | active not recruiting | Phase 2 | 237 | GlaxoSmithKlineINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | active not recruiting | Phase 3 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 22 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT02375204 | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors | active not recruiting | Phase 3 | 420 | Alliance for Clinical Trials in OncologyOTHER | 12 | Jun 16, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | active not recruiting | Phase 3 | 1,174 | AstraZenecaINDUSTRY | 17 | Jun 15, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07607431 | Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort(AWARE) | active not recruiting | — | 214 | Rigshospitalet, DenmarkOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07635108 | MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)(PINPOINT) | not yet recruiting | N/A | 48 | Odense University HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04421963 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib(ROSY-O) | active not recruiting | Phase 3 | 185 | AstraZenecaINDUSTRY | 23 | Jun 12, 2026 | clinicaltrials |
| NCT04537195 | Effects of a Lay-led Anxiety and Depression Self-management Program for Cancer Patients(ADSMP-C) | active not recruiting | N/A | 234 | University of AarhusOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04774198 | Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy | completed | — | 58 | Rigshospitalet, DenmarkOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05195502 | Mapping the Human Colon Using Single Cell Sequencing(COLATA) | completed | — | 40 | Bispebjerg HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT04572165 | Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data | completed | — | 194,928 | Novo Nordisk A/SINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 841 | PfizerINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT05620238 | Home Treatment With Carfilzomib in Patients With Multiple Myeloma | completed | — | 9 | Thomas LundOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03270982 | Comprehensive Segmental Revision System | active not recruiting | — | 105 | Zimmer BiometINDUSTRY | 3 | Jun 9, 2026 | clinicaltrials |
| NCT05192031 | Implementation of Smoking Cessation Support During Lung Cancer Workup | completed | N/A | 86 | Vejle HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03301220 | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | completed | Phase 3 | 390 | Janssen Research & Development, LLCINDUSTRY | 24 | Jun 8, 2026 | clinicaltrials |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(PSMAddition) | active not recruiting | Phase 3 | 1,140 | Novartis PharmaceuticalsINDUSTRY | 19 | Jun 8, 2026 | clinicaltrials |
| NCT05904119 | Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study(LEGATO) | recruiting | Phase 3 | 411 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Jun 8, 2026 | clinicaltrials |
| NCT07145450 | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | recruiting | Phase 1 / Phase 2 | 96 | Anocca ABOTHER_GOV | 4 | Jun 8, 2026 | clinicaltrials |
| NCT07634263 | Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study | not yet recruiting | — | 50 | Odense University HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07629609 | BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer(BEFAST) | recruiting | Phase 2 | 90 | Barbara Malene FischerOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | terminated | Phase 3 | 358 | Novartis PharmaceuticalsINDUSTRY | 26 | Jun 4, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT07627022 | Impact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer(APPAREL) | not yet recruiting | N/A | 32 | University Hospital Schleswig-HolsteinOTHER | 4 | Jun 4, 2026 | clinicaltrials |
| NCT00903591 | Study of Radiation Exposure and Bilateral Breast Cancer | active not recruiting | — | 1,699 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Jun 3, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT07552584 | Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection(BREATHE) | recruiting | N/A | 1,000 | Vejle HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623473 | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation(NIMBLE) | recruiting | — | 1,800 | Herlev and Gentofte HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04303858 | A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 | 189 | Hoffmann-La RocheINDUSTRY | 5 | Jun 2, 2026 | clinicaltrials |
| NCT06950385 | Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis(SERENTA) | recruiting | Phase 3 | 168 | Rapamycin Holdings Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT07380815 | Physical Activity During Radiation Therapy for Lung Cancer(APART-LUNG) | completed | — | 20 | University Hospital Schleswig-HolsteinOTHER | 4 | Jun 2, 2026 | clinicaltrials |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)(MTAPESTRY 103) | active not recruiting | Phase 1 | 120 | AmgenINDUSTRY | 16 | Jun 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials